

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-183)	DONISLECEL
PRONUNCIATION	doe nis' le sel
THERAPEUTIC CLAIM	Treatment of brittle type 1 diabetes

DESCRIPTION

The product is a cellular therapy developed to treat brittle type 1 diabetes and consists of allogeneic human islets of Langerhans suspended in supplemented transplant medium. Allogeneic islets of Langerhans are liberated from the pancreas of a deceased donor using enzymatic digestion, purified using a continuous density gradient, washed, suspended in supplemented culture medium, and cultured at 37°C/5% CO₂ while the recipient is prepared for transplant. Islets are then harvested by centrifugation, suspended in supplemented transplant medium, and filled into an infusion bag. The final islet product is then infused into the patient at an appropriate transplantation site, such as the hepatic portal vein.

TRADEMARK	None as yet
SPONSOR	CellTrans, Inc.
CODE DESIGNATIONS	None

SCS